Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Restructuring Costs: 2021-2023

Historic Restructuring Costs for Theravance Biopharma (TBPH) over the last 3 years, with Dec 2023 value amounting to $2.7 million.

  • Theravance Biopharma's Restructuring Costs fell 61.10% to $1.2 million in Q2 2023 from the same period last year, while for Jun 2023 it was $38.7 million, marking a year-over-year increase of 19.33%. This contributed to the annual value of $2.7 million for FY2023, which is 78.63% down from last year.
  • Per Theravance Biopharma's latest filing, its Restructuring Costs stood at $2.7 million for FY2023, which was down 78.63% from $12.8 million recorded in FY2022.
  • Over the past 5 years, Theravance Biopharma's Restructuring Costs peaked at $20.1 million during FY2021, and registered a low of $2.7 million during FY2023.
  • Over the past 3 years, Theravance Biopharma's median Restructuring Costs value was $12.8 million (recorded in 2022), while the average stood at $11.9 million.
  • Data for Theravance Biopharma's Restructuring Costs shows a maximum YoY slumped of 78.63% (in 2023) over the last 5 years.
  • Theravance Biopharma's Restructuring Costs (Yearly) stood at $20.1 million in 2021, then slumped by 36.26% to $12.8 million in 2022, then crashed by 78.63% to $2.7 million in 2023.